• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia.

作者信息

Wang Eunice S, Zeidan Amer, Tan Wei, Wilding Gregory E, Ford Laurie Ann, Wallace Paul K, Hahn Theresa E, Battiwalla Minoo, McCarthy Philip L, Wetzler Meir

出版信息

Leuk Lymphoma. 2012 Oct;53(10):2085-8. doi: 10.3109/10428194.2011.603450. Epub 2011 Sep 6.

DOI:10.3109/10428194.2011.603450
PMID:21740302
Abstract
摘要

相似文献

1
Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia.在异基因干细胞移植前，使用吉妥珠单抗奥唑米星和阿糖胞苷进行细胞减灭术治疗复发/难治性急性髓系白血病。
Leuk Lymphoma. 2012 Oct;53(10):2085-8. doi: 10.3109/10428194.2011.603450. Epub 2011 Sep 6.
2
Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.分次给予吉妥珠单抗奥佐米星联合 3+7 诱导化疗作为首次复发的年轻急性髓系白血病患者的挽救治疗。
Ann Hematol. 2012 Dec;91(12):1871-7. doi: 10.1007/s00277-012-1528-9. Epub 2012 Jul 21.
3
Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?分次给予的吉妥珠单抗奥唑米星联合中剂量阿糖胞苷和柔红霉素作为极高危急性髓系白血病患者的挽救治疗：通向降低强度预处理移植的桥梁？
Ann Hematol. 2017 Mar;96(3):363-371. doi: 10.1007/s00277-016-2899-0. Epub 2016 Dec 23.
4
Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia.MIDAM方案治疗复发或难治性急性髓系白血病患者缓解后策略的结局与影响
Am J Hematol. 2019 Jan;94(1):E32-E35. doi: 10.1002/ajh.25332. Epub 2018 Nov 25.
5
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy.在首次诱导治疗难治的急性髓性白血病中，采用大剂量阿糖胞苷和米托蒽醌联合全反式维甲酸及吉妥珠单抗奥唑米星进行挽救治疗。
Haematologica. 2016 Jul;101(7):839-45. doi: 10.3324/haematol.2015.141622. Epub 2016 Apr 1.
6
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.吉妥珠单抗奥佐米星可降低儿童急性髓系白血病患者的微小残留病。
Cancer. 2013 Nov 15;119(22):4036-43. doi: 10.1002/cncr.28334. Epub 2013 Sep 4.
7
Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.低剂量吉妥珠单抗奥唑米星治疗老年复发性急性髓系白血病
Haematologica. 2003 Dec;88(12):ECR37.
8
Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia.阿扎胞苷和吉妥珠单抗奥唑米星用于高危急性髓性白血病的移植后维持治疗。
Br J Haematol. 2015 Jun;169(5):756-9. doi: 10.1111/bjh.13248. Epub 2014 Dec 17.
9
Successful treatment with gemtuzumab ozogamicin and donor lymphocyte infusion for acute myeloid leukemia relapsing after allogeneic stem cell transplantation.吉妥珠单抗奥唑米星联合供体淋巴细胞输注成功治疗异基因干细胞移植后复发的急性髓系白血病。
Int J Hematol. 2011 Dec;94(6):580-2. doi: 10.1007/s12185-011-0967-8. Epub 2011 Dec 2.
10
Gemtuzumab ozogamicin plus cytarabine in elderly patients with relapsed or refractory acute myeloid leukaemia.吉妥珠单抗奥唑米星联合阿糖胞苷治疗复发或难治性急性髓系白血病老年患者
Br J Haematol. 2008 May;141(5):744-5. doi: 10.1111/j.1365-2141.2008.07096.x. Epub 2008 Mar 27.

引用本文的文献

1
Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.吉妥珠单抗奥佐米星治疗急性髓系白血病。
Expert Rev Clin Pharmacol. 2018 Jun;11(6):549-559. doi: 10.1080/17512433.2018.1478725. Epub 2018 Jun 11.
2
Early versus late preemptive allogeneic hematopoietic cell transplantation for relapsed or refractory acute myeloid leukemia.早期与晚期抢先异基因造血细胞移植治疗复发或难治性急性髓系白血病
Biol Blood Marrow Transplant. 2014 Sep;20(9):1369-74. doi: 10.1016/j.bbmt.2014.05.013. Epub 2014 May 24.